HC Wainwright cut their FY2028 earnings per share estimates for shares of ImmunoPrecise Antibodies in a research note issued ...

Stock analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for CalciMedica in a report issued on Tuesday, April 1st. HC Wainwright analyst J. Pantginis expects that the company ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright analyst Douglas Tsao views the agreement of joint stipulation between Arcutis Biotherapeutics (ARQT) and Padagis to the ongoing ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Ryvyl (RVYL – Research Report) today. The company’s shares closed yesterday at ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

A webcast replay will be available on the VYNE website for 90 days following the event. About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a Buy recommendation. As of January 19, 2024, the average one-year price ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...